Clinical Trial Update: Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of a new dilution and injection volume of abobotulinumtoxinA for glabellar lines has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• AbobotulinumtoxinA (abobotulinumtoxinA)

Snippet

Sponsor: Galderma R&D | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2021-05-11